S&W Seed Company (SANW) Forms $3.50 Double Bottom; Progenics Pharmaceuticals (PGNX) Shorts Increased By 0.02%

Progenics Pharmaceuticals Inc (NASDAQ:PGNX) had an increase of 0.02% in short interest. PGNX’s SI was 7.27 million shares in March as released by FINRA. Its up 0.02% from 7.26M shares previously. With 952,900 avg volume, 8 days are for Progenics Pharmaceuticals Inc (NASDAQ:PGNX)’s short sellers to cover PGNX’s short positions. The SI to Progenics Pharmaceuticals Inc’s float is 10.37%. The stock increased 1.06% or $0.07 during the last trading session, reaching $6.69. About 1.45 million shares traded or 11.48% up from the average. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 48.41% since March 4, 2017 and is uptrending. It has outperformed by 31.71% the S&P500.

S&W Seed Company (SANW) formed double bottom with $3.22 target or 8.00% below today’s $3.50 share price. S&W Seed Company (SANW) has $85.18M valuation. The stock increased 1.45% or $0.05 during the last trading session, reaching $3.5. About 54,306 shares traded. S&W Seed Company (NASDAQ:SANW) has declined 4.21% since March 4, 2017 and is downtrending. It has underperformed by 20.91% the S&P500.

Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company has market cap of $470.11 million. The companyÂ’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant and/or recurrent pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen -targeted positron emission topography (PET) imaging agent for prostate cancer. It currently has negative earnings. The Company’s clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and EXINI bone BSI range of prostate cancer bone scan indexing products.

Among 5 analysts covering Progenics Pharm (NASDAQ:PGNX), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Progenics Pharm had 11 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Needham with “Buy” on Tuesday, June 20. As per Wednesday, August 9, the company rating was maintained by Cantor Fitzgerald. The firm earned “Buy” rating on Thursday, June 8 by Jefferies. Jefferies maintained it with “Buy” rating and $12.0 target in Tuesday, September 26 report. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Thursday, August 6 by Brean Capital. The rating was downgraded by Zacks on Friday, August 7 to “Buy”. Jefferies upgraded Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) rating on Friday, October 23. Jefferies has “Buy” rating and $9 target. The firm has “Buy” rating by Aegis Capital given on Thursday, October 27. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) earned “Strong Buy” rating by Needham on Monday, February 6. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, August 7 by Needham.

Investors sentiment decreased to 1.11 in Q3 2017. Its down 0.18, from 1.29 in 2017Q2. It is negative, as 22 investors sold Progenics Pharmaceuticals, Inc. shares while 34 reduced holdings. 16 funds opened positions while 46 raised stakes. 58.90 million shares or 4.84% less from 61.90 million shares in 2017Q2 were reported. Fifth Third Bank, Ohio-based fund reported 5,000 shares. Envestnet Asset Mngmt Inc holds 0% or 3,845 shares. Baker Bros Lp invested in 0.19% or 3.15M shares. Citigroup invested in 155,203 shares or 0% of the stock. Natixis has invested 0% in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Opus Point Mngmt Limited Liability Company owns 0.14% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 21,782 shares. Clarivest Asset Mngmt Ltd Company owns 186,174 shares for 0.03% of their portfolio. State Board Of Administration Of Florida Retirement Systems accumulated 45,340 shares. Manufacturers Life Ins The holds 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 61,054 shares. Dekabank Deutsche Girozentrale stated it has 9,000 shares. Employees Retirement Of Texas invested in 114,000 shares or 0.01% of the stock. Royal National Bank Of Canada has 6,338 shares for 0% of their portfolio. Phocas Financial Corporation has 1.50M shares for 0.92% of their portfolio. Schwab Charles Investment Management has 322,424 shares. Northern Trust accumulated 0% or 886,616 shares.

Investors sentiment decreased to 0.73 in 2017 Q3. Its down 0.04, from 0.77 in 2017Q2. It turned negative, as 5 investors sold S&W Seed Company shares while 10 reduced holdings. 5 funds opened positions while 6 raised stakes. 12.40 million shares or 9.49% more from 11.33 million shares in 2017Q2 were reported. Smith Moore has invested 0.01% in S&W Seed Company (NASDAQ:SANW). Blackrock holds 0% or 66,614 shares in its portfolio. Vanguard Gru reported 0% stake. Koshinski Asset Mngmt invested in 0.19% or 179,878 shares. Wynnefield Cap has 4.01M shares for 4.52% of their portfolio. Thomson Horstmann & Bryant owns 488,744 shares or 0.21% of their US portfolio. Vertex One Asset Inc reported 34,065 shares. Wellington Gp Limited Liability Partnership accumulated 0% or 47,775 shares. Moreover, Neuberger Berman Ltd Llc has 0% invested in S&W Seed Company (NASDAQ:SANW). Barclays Public Ltd Co invested in 87 shares. 2,311 were reported by Morgan Stanley. Cutter Commerce Brokerage invested 0.77% of its portfolio in S&W Seed Company (NASDAQ:SANW). Comml Bank Of America Corporation De accumulated 0% or 2 shares. Royal Bancshares Of Canada owns 12 shares. Old West Ltd Liability Corp invested 0.43% in S&W Seed Company (NASDAQ:SANW).

Since October 1, 2017, it had 0 buys, and 2 insider sales for $7,816 activity. The insider Szot Matthew K sold 1,100 shares worth $4,400.